References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
- Barrett-Connor E, Ensrud K E, Harper K, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25: 919–930
- Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 2002; 287: 847–857
- Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137
- Vogel V G, Costantino J P, Wickerham D L, et al. Effects of tamoxifen on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene P-2 trial. JAMA 2006; 295: 2727–2741
- Melnikow J, Kuenneth C, Helms L J, et al. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 2006; 107: 950–958